Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00391482 · ClinicalTrials.gov registry record · Phase 2
Study to Reduce Intravenous Exposures (STRIVE)
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 750
- Enrollment target
NCT00391482: Completed Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
NCT00391482 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 750 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (464% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00391482, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 750 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a six-session, small group behavioral intervention based on "peer-volunteer activism" is effective in (1) decreasing distributive sharing of syringes and other injection paraphernalia and (2) increasing utilization of HCV-related healthcare services among HCV-infected injection drug users
Interventions
- BEHAVIORAL Peer Mentoring Intervention for HCV-Infected IDUs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2002-06 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
What the finished NCT00391482 record still lists
NCT00391482 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (464% higher).
The record links to 0 conditions, and to 1 intervention - of which Peer Mentoring Intervention for HCV-Infected IDUs is the first listed.
NCT00391482 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00391482 about?
NCT00391482 is a clinical study titled "Study to Reduce Intravenous Exposures (STRIVE)". The purpose of this study is to determine whether a six-session, small group behavioral intervention based on "peer-volunteer activism" is effective in (1) decreasing distributive sharing of syringes and other injection paraphernalia and (2) increasing utilization of HCV-related healthcare services ...
What is the current status of trial NCT00391482?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 750 participants. The study started on 2002-06. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00391482?
The interventions under investigation include: Peer Mentoring Intervention for HCV-Infected IDUs (BEHAVIORAL).
Who is sponsoring clinical trial NCT00391482?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00391482's enrollment target sits among peer trials
750 43rd of 2000 higher than 1,957 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia